Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus; Jürgen K Rockstroh; Keith Henry; Jean-Michel Molina; Joseph Gathe; Srinivasan Ramanathan; Xuelian Wei; Kitty Yale; Javier Szwarcberg; Kirsten White; Andrew K Cheng; Brian P Kearney; GS-236-0103 Study Team; Jan Gerstoft

doi:10.1016/S0140-6736(12)60918-0

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, Jürgen K Rockstroh, Keith Henry, Jean-Michel Molina, Joseph Gathe, Srinivasan Ramanathan, Xuelian Wei, Kitty Yale, Javier Szwarcberg, Kirsten White, Andrew K Cheng, Brian P Kearney, GS-236-0103 Study Team, Jan Gerstoft

341 Citationer (Scopus)

Abstract

The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	379
Udgave nummer	9835
Sider (fra-til)	2429-38
Antal sider	10
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(12)60918-0
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/S0140-6736(12)60918-0

Fingeraftryk

Dyk ned i forskningsemnerne om 'Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., Cheng, A. K., Kearney, B. P., GS-236-0103 Study Team, & Gerstoft, J. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, 379(9835), 2429-38. https://doi.org/10.1016/S0140-6736(12)60918-0

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. / DeJesus, Edwin; Rockstroh, Jürgen K; Henry, Keith et al.
I: Lancet, Bind 379, Nr. 9835, 2012, s. 2429-38.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

DeJesus, E, Rockstroh, JK, Henry, K, Molina, J-M, Gathe, J, Ramanathan, S, Wei, X, Yale, K, Szwarcberg, J, White, K, Cheng, AK, Kearney, BP, GS-236-0103 Study Team & Gerstoft, J 2012, 'Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial', Lancet, bind 379, nr. 9835, s. 2429-38. https://doi.org/10.1016/S0140-6736(12)60918-0

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429-38. doi: 10.1016/S0140-6736(12)60918-0

DeJesus, Edwin ; Rockstroh, Jürgen K ; Henry, Keith et al. / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : a randomised, double-blind, phase 3, non-inferiority trial. I: Lancet. 2012 ; Bind 379, Nr. 9835. s. 2429-38.

@article{452de87c6a404f4dac6b7e42fb54fd67,

title = "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial",

abstract = "The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.",

keywords = "Adenine, Adult, Anti-HIV Agents, Carbamates, Deoxycytidine, Double-Blind Method, Drug Combinations, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Oligopeptides, Phosphonic Acids, Pyridines, Quinolones, Ritonavir, Thiazoles",

author = "Edwin DeJesus and Rockstroh, {J{\"u}rgen K} and Keith Henry and Jean-Michel Molina and Joseph Gathe and Srinivasan Ramanathan and Xuelian Wei and Kitty Yale and Javier Szwarcberg and Kirsten White and Cheng, {Andrew K} and Kearney, {Brian P} and {GS-236-0103 Study Team} and Jan Gerstoft",

year = "2012",

doi = "10.1016/S0140-6736(12)60918-0",

language = "English",

volume = "379",

pages = "2429--38",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9835",

}

TY - JOUR

T1 - Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection

T2 - a randomised, double-blind, phase 3, non-inferiority trial

AU - DeJesus, Edwin

AU - Rockstroh, Jürgen K

AU - Henry, Keith

AU - Molina, Jean-Michel

AU - Gathe, Joseph

AU - Ramanathan, Srinivasan

AU - Wei, Xuelian

AU - Yale, Kitty

AU - Szwarcberg, Javier

AU - White, Kirsten

AU - Cheng, Andrew K

AU - Kearney, Brian P

AU - GS-236-0103 Study Team

AU - Gerstoft, Jan

PY - 2012

Y1 - 2012

N2 - The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

AB - The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

KW - Adenine

KW - Adult

KW - Anti-HIV Agents

KW - Carbamates

KW - Deoxycytidine

KW - Double-Blind Method

KW - Drug Combinations

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Male

KW - Middle Aged

KW - Oligopeptides

KW - Phosphonic Acids

KW - Pyridines

KW - Quinolones

KW - Ritonavir

KW - Thiazoles

U2 - 10.1016/S0140-6736(12)60918-0

DO - 10.1016/S0140-6736(12)60918-0

M3 - Journal article

C2 - 22748590

SN - 0140-6736

VL - 379

SP - 2429

EP - 2438

JO - Lancet

JF - Lancet

IS - 9835

ER -